Could Zimmer Biomet Holdings, Inc. (ZBH) Change Direction After Today’s Big Decline?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Logo

The stock of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a huge mover today! The stock decreased 2.88% or $4.11 during the last trading session, reaching $138.5. About 684,677 shares traded. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has risen 6.81% since September 13, 2018 and is uptrending. It has outperformed by 6.81% the S&P500.
The move comes after 6 months negative chart setup for the $28.91 billion company. It was reported on Sep, 13 by We have $128.81 PT which if reached, will make NYSE:ZBH worth $2.02 billion less.

Analysts await Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to report earnings on October, 25. They expect $1.76 earnings per share, up 7.98 % or $0.13 from last year’s $1.63 per share. ZBH’s profit will be $367.33 million for 19.67 P/E if the $1.76 EPS becomes a reality. After $1.93 actual earnings per share reported by Zimmer Biomet Holdings, Inc. for the previous quarter, Wall Street now forecasts -8.81 % negative EPS growth.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Ratings Coverage

Among 7 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Zimmer Biomet Holdings has $15800 highest and $117 lowest target. $142.25’s average target is 2.71% above currents $138.5 stock price. Zimmer Biomet Holdings had 15 analyst reports since March 25, 2019 according to SRatingsIntel. The stock of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has “Underweight” rating given on Monday, April 15 by Barclays Capital. As per Monday, September 9, the company rating was maintained by Wells Fargo. Citigroup maintained it with “Buy” rating and $15800 target in Friday, August 2 report. The stock has “Hold” rating by Piper Jaffray on Thursday, June 20. The stock has “Outperform” rating by Evercore on Monday, April 8. Cantor Fitzgerald maintained it with “Buy” rating and $135 target in Monday, March 25 report. The rating was upgraded by Barclays Capital to “Equal-Weight” on Tuesday, July 30. The stock of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) earned “Overweight” rating by Morgan Stanley on Monday, July 29.

More notable recent Zimmer Biomet Holdings, Inc. (NYSE:ZBH) news were published by: which released: “NYSE: ZBH Investor Notice: Update in Lawsuit against Zimmer Biomet Holdings Inc announced by Shareholders Foundation – Yahoo Finance” on June 03, 2019, also with their article: “Update in Lawsuit for Investors in shares of Zimmer Biomet Holdings Inc (NYSE: ZBH) announced by Shareholders Foundation – Yahoo Finance” published on April 24, 2019, published: “ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zimmer Biomet Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm – GlobeNewswire” on September 03, 2019. More interesting news about Zimmer Biomet Holdings, Inc. (NYSE:ZBH) were released by: and their article: “Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios – Benzinga” published on August 15, 2019 as well as‘s news article titled: “Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Zimmer Biomet Holdings, Inc. (ZBH) – PRNewswire” with publication date: August 30, 2019.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, makes, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company has market cap of $28.91 billion. It operates through four divisions: Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic , and Dental. It currently has negative earnings. The firm provides orthopedic reconstructive products, such as knee and hip reconstructive products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.